a Numerous studies propose that epigallocatechin-3-gallate (EGCG), an abundant polyphenol in green tea, has anti-cancer properties. However, its mechanism of action in breast cancer remains unclear. This study investigated the capacity of EGCG to suppress breast cancer cell growth in vitro and in vivo, characterizing the underlying mechanisms, focusing on the effect of EGCG on glucose metabolism. EGCG reduced breast cancer 4T1 cell growth in a concentration-(10-320 μM) and time-(12-48 h) dependent manner. EGCG induced breast cancer apoptotic cell death at 24 h, as evidenced by annexin V/PI, caspase 3, caspase 8 and caspase 9 activation. Furthermore, EGCG affected the expression of 16 apoptosis-related genes, and promoted mitochondrial depolarization. EGCG induced autophagy concentration-dependently in 4T1 cells by modulating the levels of the autophagy-related proteins Beclin1, ATG5 and LC3B.
Introduction
With over one million new cases diagnosed worldwide every year, breast cancer represents a significant health problem. 1 Despite advances in early detection, breast cancer remains a major disease burden, due to an increase in its incidence, particularly in the developing world. [2] [3] [4] The dramatic increase in breast cancer incidence mandates for efforts to prevent this disease, 5, 6 with the evaluation of agents with chemopreventive properties being a critical component. Numerous dietary bioactives have been reported to have chemopreventive effects in a large number of cancer patients. 7 Among these, epigallocatechin-3-gallate (EGCG), the most abundant catechin in green tea, 8 presents multiple health benefits. [9] [10] [11] For example, EGCG has been documented to have beneficial roles in various diseases like diabetes, 12 Parkinson's, 13 stroke, 14 obesity, 15 as well as cancer. 16 Mechanistically, EGCG has been proposed to block and inhibit various signaling pathways that lead to the initiation and progression of various types of cancers. However, the exact mechanisms related to the preventive activity of EGCG in breast cancer are incompletely understood. Among the multiple mechanisms proposed, EGCG has been recently shown to affect the pathways related to glucose metabolism. Glucose metabolism allows for energy to be coupled in the form of ATP, through the oxidation of its carbon bonds. This process is essential for sustaining all mammalian life. Glycolysis, a critical metabolic pathway in the metabolism of glucose, is common in anaerobic environments. However, unlike normal cells, cancer cells can instead rely primarily on glycolysis to generate energy, even in an aerobic environment. This phenomenon, termed aerobic glycolysis or the Warburg effect, 17 allows tumor cells to generate a high rate of glycolytic intermediates, which become substrates for several biosynthetic pathways crucial for cell proliferation and cancer progression. Thus, agents, such as EGCG, that can affect glucose metabolism in cancer cells are of particular a interest. However, there is a dearth of information on the effect of EGCG on glucose metabolism in breast cancer. In this study, we investigated the anticancer effect of EGCG in breast cancer in vitro and in vivo, as well as the underlying molecular mechanisms, focusing on the effect of EGCG on tumor glucose metabolism. Our data show that EGCG inhibits the growth of breast cancer cells in vitro and in vivo, by inducing apoptosis and altering autophagy. Furthermore, EGCG strongly suppresses the activity of the enzymes hexokinase (HK), phosphofructokinase (PFK), and lactic dehydrogenase (LDH), enzymes related to the glycolytic pathway, indicating that modulating glucose metabolism could represent a key event in EGCG's anticancer effect in breast cancer.
Materials and methods

Chemicals and reagents
EGCG ( purity >98%) was purchased from Aladdin Industrial Corporation (Shanghai, China). The CCK8 kit was purchased from Biosharp (Hefei, China). The annexin V-FITC/PI kit was purchased from Dojindo (Shanghai, China). The kits for caspase 3, caspase 8, caspase 9 activity, JC-1, ATP levels, AdmCherry-GFP-LC3B and the Bradford protein assay were purchased from Beyotime (Nantong, China). The kits to determine glucose, lactic acid, HK activity, PFK activity, PK activity and LDH activity were purchased from Jiancheng (Nanjing, China). The PureLink RNA Mini Kit was purchased from Ambion (Shanghai, China). The ReverTra Ace qPCR RT master mix and the SYBR Green Realtime PCR master mix were purchased from TOYOBO (Shanghai, China). The designed oligonucleotide primers were generated by TsingKe (Beijing, China). The RIPA lysis buffer and Halt protease inhibitor cocktail were purchased from Applygen (Beijing, China). The 2× Laemmli sample buffer and the PVDF membranes were purchased from Bio-Rad (Shanghai, China). The HIFα, Beclin1, ATG5, LC3B and β-actin antibodies were purchased from Cell Signaling Technology Company (Shanghai, China). The GLUT1 antibody was purchased from Abcam (Shanghai, China), while the VEGF antibody was from Fisher Scientific (Wuhan, China). Hematoxylin and eosin were purchased from GuGe (Wuhan, China). 5-Fluorouracil (5-FU) was purchased from Meilunbio (Dalian, China).
Cell culture
The 4T1 cell line was purchased from the Cell Bank of Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China), while the HC11 mammary epithelial cells were from the American Type Culture Collection (Manassas, VA).
We have not authenticated these cell lines; however we routinely test for mycoplasma contamination in every cell line every three months. These cells were grown as monolayers in a specific medium and under the conditions suggested by the vendor. Both cell lines were characterized by cell morphology and growth rate and passaged in our laboratory for less than 6 months after being received. The cells were passaged every 2-3 days at a ratio of 1 : 3.
Cell viability
Cell viability was measured by using the Cell Counting Kit-8 (CCK8). Briefly, the cells seeded in 96-well plates overnight were treated with escalating concentrations of EGCG for 12, 24 or 48 h. Following incubation, the CCK8 reagent was added, and incubated for 2.5 h. The optical density at 450 nm was measured using an Infinite® microplate reader (Tecan; Männedorf, Switzerland).
Annexin V-FITC/PI staining
Cells were seeded overnight and then treated with various concentrations of EGCG for 24 h and 48 h. Following incubation, the cells were collected, washed twice with PBS, stained with annexin V-FITC (Dojindo; Shanghai, China) and propidium iodide (0.5 µg ml −1 ), and then analyzed by using a FACScaliber (BD Biosciences; San Jose, CA).
q-PCR
Cells were seeded overnight and then treated with various concentrations of EGCG for 24 h. Following incubation, total RNA was isolated using the PureLink RNA Mini Kit and transcribed reversely by using the ReverTra Ace qPCR RT master mix with the Veriti thermal cycler (Thermo Fisher Scientific; Waltham, MA). The levels of mRNA were detected by using the SYBR Green Realtime PCR master mix and were monitored by using the StepOne Realtime PCR system (Thermo Fisher Scientific; Waltham, MA).
JC-1 staining
The mitochondrial membrane potential (ΔΨ m ) was determined by fluorescence microscopy using the JC-1 cationic dye. 17 Briefly, after treatment with EGCG for 24 h, the cells were washed twice with PBS, and incubated with the JC-1 reagent for 20 min at 37°C. Subsequently, the cells were washed twice with JC-1 staining buffer and the fluorescence of both the JC-1 monomer (green) and aggregates (red) was detected by using a fluorescence microscope (Nikon Ti-s; Tokyo, Japan).
Caspase activity
Caspase 3, 8 and caspase 9 activities were measured using caspase activity assay kits, following the manufacturers' protocol (Beyotime; Nantong, China). Briefly, caspase activities were measured by the chromogenic products of caspase substrates: Ac-DEVE-pNA (caspase3 substrate), Ac-IETD-pNA (caspase8 substrate) and Ac-LEHD-pNA (caspase9 substrate). After treating with EGCG for 24 h, the cells were harvested and centrifuged at 600g, at 4°C for 5 min. After washing with cold PBS twice, the cells were resuspended with 50 µl lysis buffer and incubated on ice for 15 min. Following centrifugation at 18 000g, at 4°C for 15 min, the supernatant was transferred into cold fresh tubes. Then, 50 µl cell extract, 40 µl buffer and 10 µl of specific caspase substrate: Ac-DEVE-pNA, Ac-IETD-pNA and Ac-LEHD-pNA were mixed together and incubated at 37°C for 80 min. Following the incubation period, the absorbance of the yellow pNA cleavage products was determined at 405 nm in a microplate reader (Tecan; Männedorf, Switzerland). Concurrently, the protein content in the cell lysates was determined to normalize the results by the protein content.
Western blot
Following treatment with EGCG for 24 h, the cells were lysed with RIPA lysis buffer and total cell fractions were obtained as previously described. 18 Aliquots of total fractions containing 25-40 µg protein were separated using 10-12.5% (w/v) polyacrylamide gel electrophoresis and were electroblotted to PVDF membranes. The membranes were probed overnight with primary antibodies (1 : 1000 dilution). β-Actin was used as the loading control. After incubation, for 90 min at room temperature, in the presence of the secondary antibody (HRPconjugated; 1 : 5000 dilution), the conjugates were visualized by chemiluminescence.
m-Cherry GFP LC3B transfection
Cells were transfected with the m-Cherry-GFP-LC3B adenovirus following the manufacturer's protocol (Beyotime; Nantong, China). Briefly, the cells were seeded in 6-well plates overnight, and then transfected with the m-Cherry-GFP-LC3B. After 24 h, the medium was replaced, and treated with EGCG for an additional 24 h. At the end of the incubation period, the cells were visualized using a confocal laser scanning microscope (Nikon; Tokyo, Japan).
Transmission electron microscopy (TEM)
The cells were seeded in 6-well plates overnight and then treated with various concentrations of EGCG for 24 h. Following treatment, the cells were washed twice with PBS, and fixed overnight with 2.5% glutaraldehyde in phosphate buffer (0.1 M, pH 7.0). After washing thrice with PBS, the cells were incubated with 1% osmium tetroxide for 2 h and subsequently washed three times with PBS, followed by dehydration with an ascending gradient of ethanol and absolute acetone. Following a transition with ethanol and Spurr resin 1 : 1, the cells were embedded with Spurr resin and incubated at 70°C overnight. Then, samples were sectioned using the ultramicrotome EM UC7 (Leica; Wetzlar, Germany), stained with uranyl acetate and alkaline lead citrate for 10 min, respectively, and scanned by using the JEM-1230 transmission electron microscope (Gatan Inc.; Tokyo, Japan).
Glucose and lactic acid levels
The cells were seeded overnight and then treated with various concentrations of EGCG (20-240 µM) for 24 h. At the end of the treatment, the cell culture medium was collected and the levels of glucose and lactic acid were determined following the manufacturers' protocol (Jiancheng; Nanjing, China). The glucose and lactic acid levels in tumors were measured following the manufacturers' protocol (Jiancheng; Nanjing, China).
Cellular ATP levels
The ATP levels were measured using an ATP assay kit. After treatment with EGCG for 24 h, the cells were lysed and centrifuged at 12 000g, at 4°C for 5 min. Subsequently, 20 µl of the supernatant was mixed together with 100 µl ATP detection working dilution, and luminance (RLU) was measured using a HRPCS5 system (Photek; East Sussex, UK). A standard curve was generated using ATP, and the protein concentration of each treatment group was determined using the Bradford Protein assay. Total ATP levels were expressed as nmol mg
protein.
Glycolysis-related enzyme activity
The cells were seeded into the 6-well plates overnight and treated with EGCG for 24 h. Following incubation, the cells were collected, washed with cold PBS and homogenized using an ultrasonic tip sonicator. After centrifugation, the supernatant was collected and used to measure the enzyme activity following the manufacturer's protocol (Jiancheng; Nanjing, China). The protein concentration was determined using the Bradford protein assay.
Animal study
All animal studies were performed in accordance with the guidelines of the Laboratory Animal Center of Zhejiang University and all animal experimental protocols were approved by the Laboratory Animal Center of Zhejiang University. 
Histological examination
At necropsy, tumors were fixed in 4% paraformaldehyde for 24 h and then processed and embedded in paraffin according to standard protocols. Tissue sections (4 μm) stained with hematoxylin and eosin (H&E) were evaluated histologically under an inverted fluorescence microscope (Nikon Eclipse TI-SR; Tokyo, Japan).
Immunofluorescence staining
The process of preparing paraffin sections was performed as described above. After antigen retrieval, immunostaining was performed by incubating slides with the primary antibody overnight at 4°C. After PBS washing, sections were incubated with a fluorophore-linked secondary antibody (Alexa Fluor 488-anti-rabbit IgG; Life Technologies). After staining, slides were mounted with DAPI and photographed under an inverted fluorescence microscope (Nikon Eclipse TI-SR; Tokyo, Japan).
Statistical analysis
The data, obtained from at least three independent experiments, were expressed as the mean ± SD. Statistical evaluation was performed using one-factor analysis of variance (ANOVA) followed by the Tukey test for multiple comparisons. P < 0.05 was regarded as being statistically significant.
Results
EGCG inhibits the growth of 4T1 breast cancer cells in culture
Our first goal was to establish the efficacy of EGCG in breast cancer cells in culture. For this purpose, we treated mouse 4T1 breast cancer cells with or without escalating concentrations of EGCG (10-320 μM) for 12, 24 or 48 h. As shown in Fig. 1A , EGCG reduced 4T1 breast cancer cell growth in a concentration-and time-dependent manner. For instance, 20 μM EGCG significantly reduced cell viability at 12 h and 24 h treatment ( p < 0.05), whereas after 48 h, 10 μM EGCG significantly reduced cell growth ( p < 0.05).
We next compared the effect of EGCG in mouse breast cancer 4T1 cells to that of the mouse mammary epithelial cells (HC11). For this purpose, we treated 4T1 cells and HC11 mammary epithelial cells with or without EGCG (40-80 μM) for 24 h. As shown in Fig. 1B , EGCG reduced cell growth more potently in 4T1 cells compared to HC11 cells. For instance, at 24 h, 80 µM EGCG reduced cell growth in 4T1 cells by 41% ( p < 0.05), respectively. In contrast, under the same experimental conditions, 80 µM EGCG for 24 h had a minimal effect on the HC11 mouse mammary epithelial cells, reducing cell growth by only 17% (Fig. 1B) .
EGCG induces cell death by apoptosis
We next explored whether the reduction in cell growth is due to an induction of apoptosis by EGCG. Staining with propidium iodide (PI) and annexin V revealed that EGCG displayed a concentration-and time-dependent induction of apoptosis ( Fig. 2A) . For example, compared to the control group, treatment with 20 µM EGCG for 24 h significantly increased the rate of early apoptosis (annexin V positive but PI negative) from 2.52 ± 0.33% to 6.95 ± 0.63%, and of late apoptosis (annexin V positive and PI positive cells) from 1.50 ± 0.22% to 8.44 ± 0.67%. This effect was even more pronounced in the 40 µM and 80 µM EGCG groups, whereas in the 160 µM and 240 µM EGCG groups, the percentage of cells in late apoptosis accounted for 20.82 ± 0.39% and 33.63 ± 0.67%, respectively (Fig. 2B) . Moreover, following treatment with 160 µM and 240 µM EGCG for 48 h, >60% of the cells experienced late apoptosis (64.11 ± 0.23% and 69.34 ± 0.87%, respectively). To note, EGCG predominantly induced apoptotic cell death, since a minimum amount of necrosis (annexin V negative but PI positive) was observed following EGCG treatment (Fig. 2B) .
Caspases play a vital role in initiating and executing cell apoptosis. 19 Thus, we determined if EGCG affected the activity of the caspases 9, 8, and 3. As shown in Fig. 2C , EGCG treatment for 24 h increased the activities of all three caspases in a concentration-dependent manner. For instance, treatment with EGCG 80 µM resulted in an increase ( p < 0.01) of 2.63, 2.70 and 2.44 fold in the activity of caspase 3, caspase 8 and caspase 9, respectively (Fig. 2C) . We next evaluated whether EGCG could affect the mitochondrial membrane potential, by means of the JC-1 probe. In healthy cells, the JC-1 probe aggregates in the normal mitochondrial matrix and emits a red fluorescence. When the mitochondrial depolarization occurs, the mitochondrial membrane becomes permeable and the JC-1 probe disperses in the cytoplasm, disaggregates into monomers, and thus, red fluorescence turns into green fluorescence. As shown in Fig. 2D , in control 4T1 cells, JC-1 accumulated in the mitochondria and majority red fluorescence with a little green fluorescence was observed. On the other hand, EGCG 20 µM reduced the red fluorescence intensity, and consequently increased the green fluorescence. This was even more pronounced in the cells treated with 40 µM EGCG (Fig. 2D) . These results suggest that EGCG induces the collapse of the mitochondrial membrane potential.
To gain insight into which apoptotic-related proteins were modified by EGCG, we performed a microarray including multiple apoptotic genes. After 24 h treatment, total RNA was extracted and reversely transcribed, and then a hierarchical clustering analysis was performed to represent the expression level of these apoptosis-related genes. Compared to control cells, EGCG increased the expression of the pro-apoptotic genes puma, caspase3, caspase8, caspase9, fas, apaf1, bax, fas-L, cytochrome c, pten, bad and smac in a concentration-dependent manner. In addition, EGCG reduced the expression levels of the anti-apoptotic genes: survivin, bcl-2, bcl-xl and c-myc (Fig. 3) .
EGCG induces autophagy in breast cancer cells
Autophagy, a lysosomal catabolic pathway of self-degradation and recycling of cellular macromolecules and organelles, is often involved in the response to treatment with anti-cancer agents. Thus, we evaluated whether autophagy played a role in the cytokinetic effect of EGCG, by exploring the key characteristic features associated with the autophagy process. These included the determination of autophagy-related proteins by immunoblotting and the formation of autophagosomes by electron microscopy.
As shown in Fig. 4A , 10 and 20 µM EGCG for 24 h significantly increased Beclin1, Atg5 and LC3B-II/LC3B-I levels. Interestingly, while 40 µM EGCG increased Beclin1 and Atg5 levels, LC3B-II/ LC3B-I levels were reduced compared to the control.
the m-Cherry-GFP-LC3B fusion protein (Ad-mCherry-GFP-LC3B). 20 Under normal conditions, the mCherry-GFP-LC3B protein disperses in the cytoplasm and displays homogeneous yellow fluorescence. When the autophagic process is triggered, the mCherry-GFP-LC3B will gather around at the membrane of the autophagosome, and yellow dots appear. However, when the autolysosome is formed, the acid environment in the lysosome quenches the fluorescence of the GFP, and as a result, only red dots are present. 21 Compared to the control, 20 µM EGCG increased the formation of autophagosomes, as depicted by the presence of yellow aggregates. Moreover, the formation of autolysosomes was observed following treatment with 40 µM EGCG, as depicted by the red aggregates and by the decrease in green fluorescence due to the acidic environment (Fig. 4B) . Finally, we evaluated whether EGCG induced autophagy in 4T1 cells by transmission electron microscopy, which allows for the direct visualization of the autophagic process. In control cells, no autophagy vacuoles were visibly present and mitochondria were clearly observed. Following treatment with 20 µM EGCG, the presence of autophagosomes with a bilayer was observed, with some organelles wrapped inside. Furthermore, in the cells treated with 40 µM EGCG, autophagosomes fused with the lysosomes were observed, suggesting that autophagy was at a more advanced stage (Fig. 4C) . Taken together, these data indicate that EGCG induces autophagy in breast cancer cells.
EGCG affects the glycolytic pathway in 4T1 breast cancer cells
Given that the glycolytic pathway can modulate the autophagy process, 22 we next explored the effect of EGCG on the multiple parameters of the glycolytic pathway. In 4T1 cells, EGCG treatment displayed a lower capacity of glucose uptake and lactic acid production in a concentration-dependent manner ( Fig. 5A and B). Glucose consumption was reduced in cells treated with EGCG becoming significant at 40 μM EGCG and reduced to 30% and 35% in the 160 and 240 µM EGCG groups, respectively, compared to the control (Fig. 5A) . Moreover, the levels of lactic acid were reduced in the 20 μM and 40 μM EGCG groups ( p < 0.05), and this reduction was even more pronounced (over 70% reduction) in the 160 and 240 μM EGCG groups ( p < 0.01; Fig. 5B ). The decrease in the consumption of glucose and in the production of lactic acid by EGCG resulted in a reduction in ATP levels (Fig. 5C ). For example, 40 μM and 80 µM EGCG reduced the ATP levels by almost half ( p < 0.01), compared to the control group, and 240 µM EGCG reduced ATP production by over 80% compared to the control ( p < 0.01; Fig. 5C ). HIF-1α, a subunit of the transcription factor HIF-1, is involved in regulating energy metabolism under hypoxia conditions. 23 On the other hand, GLUT1 is a key transporter, responsible for the uptake of glucose from blood into the cell. 24 Given that HIF1α and GLUT1 are critical players in regulating glucose metabolism, we then explored whether EGCG could affect its expression levels. As shown in Fig. 5D , EGCG markedly reduced the expression levels of HIF1α and GLUT1 in a concentration-dependent manner (Fig. 5D) .
The glycolytic enzyme hexokinase (HK) facilitates autophagy in response to glucose deprivation (HK substrate deprivation) to protect cells, suggesting that HK may function as a molecular switch from glycolysis to autophagy to ensure cellular energy homeostasis under starvation conditions. 25 Thus, we next examined the effect of EGCG on the HK enzyme activity and levels. After 24 h, EGCG inhibited the HK activity and levels in a concentration-dependent manner ( p < 0.01; Fig. 6A and B) . We then explored the effect of EGCG on the activities of PFK, PK, and LDH; all key enzymes that regulate glucose metabolism and lactic acid production. After 24 h, EGCG significantly inhibited the activities of PFK and LDH compared to the control group ( p < 0.05). On the other hand, EGCG showed a weaker effect on the activity of PK, only reaching significance during 80 µM EGCG treatment (Fig. 6A) . Furthermore, after EGCG treatment for 24 h, the mRNA expression of the HK was reduced concentration-dependently ( p < 0.05). However, the mRNA expression levels of PKM2, PFK1 and LDHA were significantly reduced only at 80 µM EGCG (Fig. 6B ).
EGCG reduces breast cancer xenograft growth
Finally, we assessed the in vivo chemotherapeutic potential of EGCG using a breast cancer syngeneic model. 4T1 cells subcutaneously injected into Balb/c mice gave rise to exponentially growing tumors. Once the tumors reached ∼300 mm 3 (Fig. 7B) .
To investigate the tumor morphology, we performed hematoxylin and eosin (H&E) staining of the excised tumors. H&E staining showed nuclear condensation, shrinkage of the nuclear membrane and less mitotic tumors in tumors treated with 20 mg kg −1 EGCG as well as in the 5-FU group, compared to the control (Fig. 7C) , suggesting that the 20 mg kg −1 EGCG and 5-FU groups damaged the inner structure of the tumor. We then examined by immunofluorescence the expression of VEGF, which stimulates the growth of new blood vessels. As shown in Fig. 7D , there is a progressive decrease in the intensity of VEGF expression from vehicle-treated to 20 mg kg −1 EGCG-treated xenografts. In particular, the expression of VEGF in 20 mg kg −1 EGCG was similar to the one observed following treatment with the 5-FU group, both groups reducing significantly the expression of VEGF, as compared to the vehicle control group. Finally, we determined the effect of EGCG on the glucose and lactic acid levels in vivo. Compared to the vehicle-treated controls, the levels of glucose in the tumors were similar in the 5 and 10 mg kg −1 EGCG, whereas 20 mg kg −1 EGCG reduced the tumor glucose levels by 34% ( p < 0.05; Fig. 7E ). Furthermore, EGCG reduced in a concentration-dependent manner the level of lactic acid in the tumor. As expected, the 5-FU group had a strong effect on the lactic acid levels. These results, together with the in vitro results described above, indicate that EGCG strongly affects glucose metabolism.
Discussion
Breast cancer remains a significant health problem and needs new therapeutic options. In the present study, we show that EGCG is effective against breast cancer in mice by suppressing glucose metabolism and inhibiting key enzymes in the glycolytic pathway. The anti-cancer efficacy of EGCG, accompanied by its selectivity toward tumor cells and its lack of toxicity, makes it a promising adjuvant drug candidate for the treatment of breast cancer. We used in vitro and in vivo preclinical models to evaluate the anticancer effect of EGCG in breast cancer. EGCG reduced breast cancer cell growth in a time-and concentration-dependent manner. A critical characteristic of EGCG was its selectivity toward cancer cells. Ideally, in order to minimize toxicity, anticancer drugs should target specifically the tumor and not the normal surrounding tissue. EGCG displayed such selectivity. Compared with the 4T1 breast cancer cell line, the normal breast epithelial cell line HC11 was more resistant to the EGCG-induced suppression of its growth. Such selectivity, if broadly confirmed, will be a significant advantage of EGCG. In addition, based on our findings from the syngeneic breast cancer mouse model, which allowed us to evaluate the therapeutic potential of EGCG in vivo, the inhibition of breast cancer growth by EGCG was strong, significantly reducing the rate of growth of 4T1 tumors by up to 34% in mice. All in all, these in vitro and in vivo models indicate that EGCG may be efficacious in breast cancer. The strong growth inhibitory effect of EGCG was due, in part, to its strong apoptotic effect. Both early apoptosis and late apoptosis increased after treatment with EGCG. As shown by the microarray heat map of differentially expressed gene levels, the expression of 16 apoptotic-related genes was differentially expressed following treatment with EGCG. For instance, EGCG significantly affected the expression of bax, bad, bcl-2, and bcl-xl, members from the Bcl-2 family, which are key players in apoptosis. 26 EGCG upregulated the expression of pro-apoptotic genes, like bad, bax, smac, 27 apaf, 28 puma, 29 and pten; and, on the other hand, EGCG inhibited the expression of anti-apoptosis genes bcl-2, bcl-xl, survivin, 30 and c-myc. 31 The modulation of these key apoptotic players provides insight into the mechanism by which EGCG induces apoptosis. Mitochondrial dysfunction is a key mediator of apoptosis, playing a vital role in the caspase cascade activation. 32, 33 After treatment with EGCG, the mitochondrial membrane potential collapsed, and this led to the activation of downstream caspases, including caspase 9 and caspase 3. Consistent with our findings, Chen et al. showed that EGCG enhanced the activity of caspase 3 and caspase 8 and the loss of mitochondrial potential in TSGH-8301 human urinary bladder carcinoma cells. 34 Moreover, EGCG was shown to induce mitochondrial membrane depolarization and promote caspase activation in pancreatic cancer cells. 35 Even though the exact mechanisms of the effects of EGCG on the mitochondria-dependent apoptosis mechanism still remain elusive, these findings strongly suggest that EGCG reduces cancer cell growth by inducing intrinsic apoptosis. Autophagy, an evolutionarily conserved catabolic process, is important in maintenance of cellular homeostasis. 36 However, autophagy dysfunction is related to many diseases, [37] [38] [39] including cancer. 40 High levels of autophagy have been observed during cell death, and it has been shown to be induced by various chemotherapeutic agents. 41 We used various complementary assays to evaluate the effect of EGCG on the process of autophagy. These included: (1) the determination of the key autophagy formation proteins; (2) the determination of autophagosome formation by confocal microscopy; and (3) the direct evaluation of the formation of the autophagosomes and their fusion with the lysosomes by TEM. Our findings indicate that EGCG strongly induced autophagy in breast cancer cells. For instance, EGCG affected the levels of the key autophagy proteins ATG5, Beclin1 and LC3B. ATG5 is a member of the autophagy related protein family, binds with ATG12 and targets autophagosome vesicles, and plays an essential role in the membrane formation of the autophagosome. 42, 43 Beclin1 is a critical protein in the process of autophagosome formation, and plays an important role in localizing autophagic proteins to form the pre-autophagosomal structure (PAS). 44 During the formation of the autophagosome, LC3B is cleaved into LC3B-I (16 kD) and a carboxyl terminal glycine. LC3B-I in the cytoplasm is then modified into the membrane-conjunct form, LC3B-II (14kD), which is positioned at both the inner and outer autophagosome membrane. When the autophagosome integrates with the lysosome, organelles and LC3B-II are degraded by lysosomal hydrolases. 45, 46 The expression of these three proteins was enhanced in the 10 and 20 μM EGCG groups, while the expression of Beclin1 and LC3B-II/LC3B-I decreased after being treated with 40 μM EGCG. These findings, together with the direct evaluation of the formation of the autophagosomes and their fusion with the lysosomes by TEM, indicate that EGCG induces autophagy in 4T1 breast cancer cells. Consistent with our findings, Satoh et al. 47 observed that EGCG induced human mesothelioma cell death by affecting autophagy, and Calgarotto et al. 48 reported that green tea as well as quercetin induced autophagy in xenografts of human leukemia HL60 cells. Mechanistically, the anti-growth effect of EGCG appears to be related to the alteration in glucose metabolism. 49, 50 Generally, tumors have an increased metabolic rate, with high energy requirements. Glycolysis offers a selective advantage to rapidly growing tumors because it can generate ATP more rapidly than oxidative phosphorylation. Furthermore, the activities of glycolytic pathway enzymes are increased in malignant cells. These increased enzymatic activities lead to reduced levels of pyruvate available to the mitochondria, resulting in a low oxidation rate through the citric acid cycle. These observations, known as aerobic glycolysis, are characterized by increased lactate production and glucose uptake, and decreased oxidative capacity. Given that glycolytic enzymes are differentially activated in tumor cells compared to normal cells, targeting glycolysis appears promising for the development of new antitumor drugs. EGCG reduced glucose uptake and lactate levels in breast cancer cells and in tumors. As a main byproduct of glycolysis, ATP is a critical marker of energy metabolism. ATP levels were reduced after being treated with EGCG, being significant starting at 40 µM, which is in agreement with the concentrations required to inhibit cell growth or induce apoptosis.
HK, PFK, PK, and LDH are four enzymes that regulate glycolysis and lactic acid formation. As the first step in glycolysis, HK phosphorylates glucose to glucose-6-phosphate (G-6-P). HK has four isoforms encoded by separate genes: HK1, HK2, HK3 and HK4. High expression levels of HK2 have been observed in the cancer cells. 51, 52 HK2 also plays a vital role in ErbB2-driven breast cancer and Kras-driven lung cancer in the mouse model. 53 PFK is the key-rate limiting enzyme in glycolysis, being regulated by many factors, e.g. ATP, ADP, citric acid, and fatty acid. Interestingly, a positive association between the increased rate of glycolysis in tumor cells and the increased activity of PFK has been shown. On the other hand, PK catalyzes the phosphoenolpyruvic acid into pyruvic acid, which is another "gatekeeper" of glycolysis. Lastly, LDH facilitates the transformation of pyruvic acid into lactic acid. In breast cancer cells, EGCG decreased the activity and levels of HK, PFK and LDH significantly, with HK and PFK being the enzymes most strongly affected by EGCG. In agreement with our findings, EGCG inhibited PFK activity in hepatic cancer cells and tumors. 54 HIF1α, one of the subunits of the HIF1 transcription factor, is highly expressed in the tumor tissue. 55 Intracellular hypoxia occurring during fast growth of cancer cells, leads to increased levels of HIF-1α. A critical function of HIF-1α is the regulation of genes encoding glucose transporters and improving the activities of glycolysis enzymes. 56 GLUT is a family of glucose transporters, and has been extensively studied in cancer cells. As a glucose family, GLUT1 is the predominant transporter usually overexpressed in tumors, including hepatic, 57 lung, 58 colorectal, 59 and breast cancer. 60 The reduction of the expression levels of HIF1α and GLUT1 by EGCG, may represent a mechanism to explain the decrease in glucose consumption following EGCG treatment. Inhibition of angiogenesis is an attractive therapy for cancer treatment. The growth and expansion of a tumor is mainly dependent on the formation of new blood vessels. Among the multiple chemical signals that regulate angiogenesis, VEGF is a critical regulator in the development of the vascular system, being commonly overexpressed in various human solid tumors, including breast cancer, and thus represents an attractive target. 61, 62 The present study revealed that EGCG inhibits VEGF expression in breast tumors. In agreement, EGCG has been shown to directly target both tumor cells and tumor vasculature, thereby inhibiting tumor growth, and angiogenesis of breast cancer, by the inhibition of HIF-1α and as well as VEGF expression. 63 Moreover, because EGCG has been shown to also protect endothelial cells through various mechanisms, [64] [65] [66] we cannot rule out that the inhibitory effect of EGCG on VEGF is, in part, the result of its effect on endothelial cells. To note, the beneficial action of EGCG still faces many challenges for clinical application, attributed, in part, to its poor bioavailability. Thus, the xenograft growth inhibition effect observed using EGCG, which was administered by intraperitoneal injections, may represent an underestimation of EGCG's potential inhibitory capacity. In this regard, extensive efforts have been made to enhance EGCG's bioavailability and stability, including EGCG's encapsulation into nanoparticles. [67] [68] [69] For example, formulating EGCG in solid lipid nanoparticles has been shown to enhance its stability and increase cytotoxicity in both breast and prostate cancer cells. 67 In addition, a lecithin formulation of a green tea catechin extract, which included EGCG, increased the bioavailability of EGCG in human breast cancer patients who consumed this lecithin formulation daily for 4 weeks. 69 Interestingly, EGCG was detectable in breast tumor tissue and was associated with anti-proliferative effects on breast cancer tissue. 69 Therefore, although not explored in our study, selecting an appropriate formulation approach, directed at enhancing EGCG's bioavailability, may represent a critical strategy to enhance EGCG's anticancer effect. In summary, EGCG, a naturally occurring compound with glycolysis inhibitory activity, has antitumor activity through the induction of apoptosis and autophagy in breast cancer cells in culture and in tumor-bearing mice. Taken together, our results point to the potential of EGCG as an adjuvant agent against breast cancer. Future studies on its potential efficacy in combination with current chemotherapeutic drugs used to treat breast cancer patients deserve further evaluation.
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